Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GPCRNASDAQ:OCULNASDAQ:VERANASDAQ:YSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGPCRStructure Therapeutics$23.74+0.4%$20.17$13.22▼$62.74$1.36B-1.35913,938 shs731,787 shsOCULOcular Therapeutix$7.71-2.4%$7.25$4.06▼$11.78$1.23B1.491.49 million shs1.71 million shsVERAVera Therapeutics$23.22-1.1%$25.27$18.53▼$51.61$1.48B1.28748,851 shs906,424 shsYSBYS Biopharma$1.25$0.35▼$1.78$344.32M0.51172,401 shs63,510 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGPCRStructure Therapeutics+1.42%+8.69%+16.27%-16.19%-35.08%OCULOcular Therapeutix+0.60%+8.07%+4.91%-0.88%+70.08%VERAVera Therapeutics+5.06%+10.24%-12.91%-30.81%-41.25%YSBYS Biopharma0.00%0.00%0.00%0.00%+366.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGPCRStructure Therapeutics2.4352 of 5 stars3.52.00.00.03.31.70.6OCULOcular Therapeutix3.4629 of 5 stars3.42.00.04.12.11.70.0VERAVera Therapeutics2.7173 of 5 stars3.63.00.00.03.42.50.0YSBYS BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGPCRStructure Therapeutics 3.00Buy$81.29242.40% UpsideOCULOcular Therapeutix 2.89Moderate Buy$16.38112.39% UpsideVERAVera Therapeutics 3.20Buy$64.67178.50% UpsideYSBYS Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest YSB, VERA, GPCR, and OCUL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/8/2025OCULOcular TherapeutixWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/8/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/18/2025OCULOcular TherapeutixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$17.003/11/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.003/4/2025OCULOcular TherapeutixJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.003/4/2025OCULOcular TherapeutixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/4/2025VERAVera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$77.00 ➝ $71.002/28/2025GPCRStructure TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform2/27/2025VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$59.00 ➝ $61.002/4/2025VERAVera TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$49.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGPCRStructure TherapeuticsN/AN/AN/AN/A$9.77 per shareN/AOCULOcular Therapeutix$63.72M19.24N/AN/A$0.79 per share9.76VERAVera TherapeuticsN/AN/AN/AN/A$1.94 per shareN/AYSBYS Biopharma$560.76M0.00N/AN/A$1.14 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGPCRStructure Therapeutics-$89.62M-$0.79N/AN/AN/AN/A-16.37%-15.68%5/8/2025 (Estimated)OCULOcular Therapeutix-$80.74M-$1.26N/AN/AN/A-283.74%-45.18%-30.87%5/6/2025 (Estimated)VERAVera Therapeutics-$95.99M-$2.75N/AN/AN/AN/A-50.13%-39.50%5/8/2025 (Estimated)YSBYS Biopharma-$21.17MN/A0.00N/AN/AN/AN/AN/AN/ALatest YSB, VERA, GPCR, and OCUL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GPCRStructure Therapeutics-$0.24N/AN/AN/AN/AN/A5/8/2025Q1 2025VERAVera Therapeutics-$0.75N/AN/AN/AN/AN/A5/6/2025Q1 2025OCULOcular Therapeutix-$0.28N/AN/AN/A$17.02 millionN/A3/3/2025Q4 2024OCULOcular Therapeutix-$0.24-$0.29-$0.05-$0.29$16.89 million$17.08 million2/27/2025Q4 2024GPCRStructure Therapeutics-$0.23-$0.22+$0.01-$0.22N/AN/A2/26/2025Q4 2024VERAVera Therapeutics-$0.83-$0.72+$0.11-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGPCRStructure TherapeuticsN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/AYSBYS BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGPCRStructure TherapeuticsN/A27.6327.63OCULOcular Therapeutix0.1913.0112.94VERAVera Therapeutics0.1713.7613.76YSBYS Biopharma0.260.940.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGPCRStructure Therapeutics91.78%OCULOcular Therapeutix59.21%VERAVera Therapeutics99.21%YSBYS Biopharma52.64%Insider OwnershipCompanyInsider OwnershipGPCRStructure Therapeutics9.43%OCULOcular Therapeutix3.50%VERAVera Therapeutics16.30%YSBYS BiopharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGPCRStructure Therapeutics13657.34 million51.86 millionOptionableOCULOcular Therapeutix230159.02 million151.71 millionOptionableVERAVera Therapeutics4063.75 million49.58 millionOptionableYSBYS Biopharma77393.06 millionN/ANot OptionableYSB, VERA, GPCR, and OCUL HeadlinesRecent News About These CompaniesYS LifeOctober 25, 2024 | yourstory.comLakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share ConsolidationOctober 3, 2024 | finanznachrichten.deLakeShore changes CEO with new executive appointmentsSeptember 5, 2024 | thepharmaletter.comLakeShore Biopharma Co Ltd Ordinary Shares LSBAugust 17, 2024 | morningstar.comLSB LakeShore Biopharma Co., LtdJuly 20, 2024 | seekingalpha.comPieris Pharmaceuticals (NASDAQ:PIRS) Stock Quotes, Forecast and News SummaryJuly 19, 2024 | benzinga.comYS Biopharma Co., Ltd.: YS Biopharma Announces Name Change to LakeShore BiopharmaMay 24, 2024 | finanznachrichten.deYS Biopharma Announces Name Change to LakeShore BiopharmaMay 24, 2024 | prnewswire.comYS Biopharma Co., Ltd.: YS Biopharma Announces Results of Extraordinary General MeetingMay 22, 2024 | finanznachrichten.deYS Biopharma Announces Results of Extraordinary General MeetingMay 21, 2024 | prnewswire.comYS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive OfficerMay 7, 2024 | prnewswire.comWith 80% ownership, YS Biopharma Co., Ltd. (NASDAQ:YS) insiders have a lot riding on the company's futureMay 7, 2024 | finance.yahoo.comYS Biopharma Co., Ltd.: YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleApril 29, 2024 | finanznachrichten.deYS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleApril 29, 2024 | prnewswire.comYS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call TranscriptApril 22, 2024 | finance.yahoo.comYS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024April 19, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024April 19, 2024 | finanznachrichten.deYS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024April 19, 2024 | markets.businessinsider.comYS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024April 19, 2024 | prnewswire.comYS Biopharma Co., Ltd.: YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus VaccineApril 18, 2024 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatThe 3 Most Talked About Investments on WallStreetBets Right NowBy Leo Miller | April 2, 2025View The 3 Most Talked About Investments on WallStreetBets Right NowThe 5 Most Oversold Stocks on the Market Are… By Thomas Hughes | March 28, 2025View The 5 Most Oversold Stocks on the Market Are… Is McDonald’s Stock Serving a Value Meal to Investors? By Jeffrey Neal Johnson | April 13, 2025View Is McDonald’s Stock Serving a Value Meal to Investors? Can IBM’s Q1 Earnings Spark a Breakout for the Stock?By Jeffrey Neal Johnson | April 23, 2025View Can IBM’s Q1 Earnings Spark a Breakout for the Stock?YSB, VERA, GPCR, and OCUL Company DescriptionsStructure Therapeutics NASDAQ:GPCR$23.74 +0.09 (+0.38%) Closing price 04:00 PM EasternExtended Trading$22.79 -0.95 (-4.00%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Ocular Therapeutix NASDAQ:OCUL$7.71 -0.19 (-2.41%) Closing price 04:00 PM EasternExtended Trading$7.71 +0.00 (+0.01%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Vera Therapeutics NASDAQ:VERA$23.22 -0.25 (-1.07%) Closing price 04:00 PM EasternExtended Trading$23.46 +0.25 (+1.06%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.YS Biopharma NASDAQ:YSBYS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
